Sample from 2008 to April 2023:
Please note that the listed transactions are a sample of the types of deals that can be created as well as just a sampling of the companies we have worked with over the time period from 2008 to 2023.
Sample from 2008 to April 2023:
Please note that the listed transactions are a sample of the types of deals that can be created as well as just a sampling of the companies we have worked with over the time period from 2008 to 2023.
With nearly three decades of experience in healthcare investment, Deerfield is positioned to deliver tailored funding and organizational support to help enable the development and commercialization across all verticals of healthcare.
Deerfield is willing to and can navigate complex situations and financing dynamics. We deploy senior investment professionals to lead transactions and tenured business executives to assist your management team in key strategic decisions.
Not an Offer or Solicitation. The videos or case studies found on this website are not an offer to sell, or a solicitation to buy, any security or instrument in, or to participate in any investment strategy with any funds, vehicles or accounts sponsored or managed by Deerfield Management Company, L.P. (“Deerfield”) or any portfolio company in which Deerfield’s investment vehicles have invested. These videos and case studies contain statements regarding the opinions, views and/or beliefs of Deerfield employees and portfolio company employees and directors, and are intended to be viewed by executives of companies that may become Deerfield portfolio companies and collaboration partners in the future. Deerfield has not received or provided any cash or non-cash compensation in exchange for these statements. Deerfield portfolio companies receive funding from affiliates of Deerfield. As a result of their relationship with Deerfield and/or the Deerfield portfolio company, the executives, directors, and/or founders of the Deerfield portfolio companies have an incentive to make positive statements about Deerfield, its investment vehicles, and affiliates. Other past or present Deerfield portfolio company executives or third parties may not necessarily share the same opinions, views or beliefs about Deerfield as those expressed in these videos and case studies. Deerfield makes no representation or warranty as to the accuracy or completeness of the information in these videos and case studies. The information is subject to change without notice or update. It should not be assumed that the portfolio companies discussed in these videos and case studies were or will be profitable or that any future portfolio companies will be profitable.
With deep expertise and capabilities in the healthcare sector, we can inform your business strategy, and provide services to allow your management team to focus on the business of the company. These include:
Strategic advice from the Deerfield investment team
Research conducted by the Deerfield Institute and Deerfield Analytics on the commercial landscape
Support from Deerfield External Operations to manage and build key business functions (Contract Negotiation, HR, IR, IT, Communications)
Deerfield offers access to scientific and technical expertise to bolster your company’s R&D engine and connect you with other cutting-edge innovators in healthcare.
Deerfield Discovery and Development (3DC) is our in-house suite of biopharma experts with skillsets across the drug development spectrum.
Deerfield’s collaborations with healthcare experts of leading universities and academic research centers represent additional assets that can support your development and business goals.
Deerfield’s CURE, an innovation ecosystem for start-ups and entrepreneurs, provides opportunities for networking, expertise development, and access to talent and innovation as a resident or as a collaborator.
Deerfield tailors flexible financing options designed to meet the needs of its corporate partners most optimally. Some of our funding options can be seen here:
Partner, Chief Partnerships Officer
917.592.1388
[email protected]
Launched in 2019 by Deerfield, the Women in Science Translational Research Symposia were created to clarify the process and route to commercialization for women scientists and in turn, help prepare them to advance their discoveries to market. The program is committed to promoting diversity of perspectives in innovation and changing this paradigm through knowledge and network creation.
In 2022, the Women in Science Translational Research Symposia formally embedded within Advancium Health Network, an independent non-profit organization launched by Deerfield Management and the Deerfield Foundation and continues to be supported by all three organizations.
New and growing enterprises face the challenge of simultaneously executing complex business strategies, building world-class operating teams, creating partnerships, and a wide range of other critical functions with limited resources. The Deerfield External Operations team partners with newly formed, and existing management teams, providing a suite of services designed to enhance company success and growth while reducing timelines to value-creating events and overall costs. While many companies require significant support early in the life cycle, the External Operations team is structured in a manner that allows Deerfield to be a long-term partner, offering services and assistance to businesses across all stages of maturity, from formation to a successful monetization event.
Services provided by the Deerfield External Operations team, include:
Beginning in 2015, Deerfield started the Deerfield Fellows program, designed to attract students with interest in pursuing healthcare or finance fields from local NYC-area colleges and universities from diverse backgrounds for an immersive summer internship program. Successful summer interns are invited to stay through a yearlong Deerfield Fellowship program, with the most successful of those graduating to become Associates at Deerfield. We are extremely proud of the work our Associates do.
Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care. As of December 2023, the firm manages more than $14.6 billion in assets.
Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.
Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries.
Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.
Established in 2006, the Deerfield Institute delivers sophisticated and timely market research, which enhances the insights available to the investment team and its partners. The Institute develops and analyzes data to advance understanding of innovations and emerging products, and it also informs on trends within the healthcare market. It has published important scientific findings in peer-reviewed journals to extend learnings to the scientific community and benefit public health at large—and ultimately patients in need. The Institute is guided by Deerfield’s core values: integrity, the pursuit of objective and unbiased research, commitment to excellence, precision and accuracy.
An affiliate of Deerfield Management, the Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to strive to improve health, accelerate innovation and promote human equity. Since its inception in 2007, the Foundation has formed numerous partnerships and invested in the advancement of children’s health, from clinics in the South Bronx to Nepal. Funds are provided through employee contributions and directly from Deerfield’s profits.
Mark Veich, Executive Director
Kerri Seacord, Treasurer
Julianna Santamaria, Executive Assistant
Abdul Khan, Program Committee Member
Adam Grossman, Program Committee Member
Ankita Shah, Program Committee Member
Bhumika Patel, Program Committee Member
Cecilia Perez, Program Committee Member
Chris Freeland, Program Committee Member
Danielle Rosato, Program Committee Member
David Griffith, Program Committee Member
Elise Wang, Program Committee Member
Emma Giegerich, Program Committee Member
Gabby Briganti, Program Committee Member
George Lytle, Program Committee Member
Giselle Pineda, Program Committee Member
H.C. Huang, Program Committee Member
Huijun Wang, Program Committee Member
Ivo Lorenz, Program Committee Member
John Limanto, Program Committee Member
Kate Lazar, Program Committee Member
Lisa Nordfors, Program Committee Member
Lizzy Baer, Program Committee Member
Luci Albertson, Program Committee Member
Mark Shtilerman, Program Committee Member
Mike Hurley, Program Committee Member
Moses Adubi, Program Committee Member
Nehan Chatoor, Program Committee Member
Nelson Barriocanal, Program Committee Member
Nicole Delgado, Program Committee Member
Rachel Chapin, Program Committee Member
Saiyara Fahmi, Program Committee Member
Sam Becker, Program Committee Member
Terence Fox-Karnal, Program Committee Member
Tori Fleek, Program Committee Member
Deerfield Management recognizes that investigators at research institutions provide much of the novel insights that advance our understanding of disease. However, at any research institution, the most commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than a research setting can typically provide.
To bridge that gap, Deerfield partners with leading research centers from across the country, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
Together with its research partners, Deerfield has created 20 spin-off companies to date that are supporting key avenues from concept to spin-out of novel therapeutic discoveries, as well as an incubator focused on innovative cardiovascular devices.
Far beyond its financial resources—with its long vision, operational expertise, and command in the life science and healthcare space for more than two decades, Deerfield is uniquely positioned to support all stages of development from early-stage to market—advancing science and enabling the translation of ideas into medicines.
Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide. To address this need, Deerfield has pioneered a model of partnership through research collaborations, which creates the potential for rapid funding and advancement of promising therapies.
Deerfield Discovery and Development (3DC) plays a critical role in progressing early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic, via design and execution of relevant experiments. 3DC partners closely with principal investigators in Deerfield’s academic collaboration network, corporate partners and entrepreneurs to provide deep functional expertise and experience across key disciplines. These include: